Anaerobic experience of fluoroquinolones and epidemiology in the United Kingdom and Europe

Infectious Diseases in Clinical Practice

Volumn 5, Issue SUPPL. 3, 1996, Pages

  MacGowan, Alasdair P ^a  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFOTETAN; CHLORAMPHENICOL; CIPROFLOXACIN; CLINAFLOXACIN; CLINDAMYCIN; IMIPENEM; LATAMOXEF; METRONIDAZOLE; OFLOXACIN; PEFLOXACIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL INFECTION; DRUG ACTIVITY; DRUG EFFICACY; EUROPE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; UNITED KINGDOM;

EID: 0029743611     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199606001-00001     Document Type: Article

References (24)

1. Betriu C, Cabronero C, Gomes M, Picazo JJ. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-89. Eur J Clin Microbiol Infect Dis. 1992;11:352-6.
2. Breuil J, Burnat C, Patey O, Dublanchet A. Survey of Bacteroides fragilis susceptibility patterns in France. J Antimicrob Chemother. 1989;24:69-75.
3. Dubreuil L, Breuil J, Dublanchet A, Sedallian A. Survey of the susceptibility pattern of Bacteroides fragilis group strains in France from 1977 to 1992. Eur J Clin Microbiol Infect Dis. 1992;11:1094-9.
4. Fox AR, Phillips I. The antibiotic sensitivity of the Bacteroides fragilis group in the United Kingdom. J Antimicrob Chemother. 1987;20:477-88.
5. Rodloff AC, Werner H, Kresken M, Jansen A, and the German Bacteroides Study Group. German multicentre study of the in vitro susceptibility of Bacteroides species. Eur J Clin Microbiol Infect Dis. 1992;11:1074-80.
6. Phillips I, King A, Nord CE, Hoffstedt B, and a European Study Group. Antibiotic sensitivity of the Bacteroides fragilis group in Europe. EurJ Clin Microbiol Infect Dis. 1992;11:292-304.
7. Hill GB, Ayers OM, Everett BQ. Susceptibilities of anaerobic gram-negative bacilli to thirteen antimicrobials and β-lactamase inhibitor combinations. J Antimicrob Chemother. 1991;28:855-67.
8. Horn R, Lavellee J, Robson HG. Susceptibilities of members of the Bacteroides fragilis group to 11 antimicrobial agents. Agents Antimicrob Chemother. 1992;36:2051-3.
9. Garcia-Rodriguez JE, Garcia-Sanchez JE. Evolution of antimicrobial susceptibility in isolates of the Bacteroides fragilis group in Spain. Rev Infect Dis. 1990;12:S142-S151.
10. Baquero F, Reig M. Resistance of anaerobic bacteria to antimicrobial agents in Spain. Eur J Clin Microbiol Infect Dis. 1992;11:1016-20.
11. King A, Boothman C, Phillips I. Comparative in vitro activity of meropenem on clinical isolates from the United Kingdom. J Antimicrob Chemother. 1989;24 Suppl A:31-45.
12. Nord CE, Lindmark A, Persson I. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria. Eur J Clin Microbiol Infect Dis. 1993;12:640-2.
13. Schito GC, Sanna A, Chazzi C, et al. In vitro activity of meropenem against clinical isolates in a multicentre study in Italy. J Antimicrob Chemother. 1989;24 Suppl A:57-72.
14. Hedberg M, Edlund C, Lindquist L, Rylander M, Nord CE. Purification and characterisation of an imipenem hydrolysing metallo-β-lactamase from Bacteroides fragilis. J Antimicrob Chemother. 1992;29:105-13.
15. Stark CA, Edlund C, Sjostedt S, Kristensen G, Nord CE. Antimicrobial resistance in human oral and intestinal anaerobic microfloras. Antimicrob Agents Chemother. 1993; 37:1665-9.
16. O'Donoghue MAT, Potter J, Allen KD. Metronidazole-resistant Bacteroides fragilis wound infection. J Infect. 1992;25:211-4.
17. King A, Phillips I. The comparative in vitro activity of eight newer quinolones and naladixic acid. J Antimicrob Chemother. 1986;18: Suppl D:1-20.
18. Gruneberg RN, Felmingham D, O'Hare MD, et al. The comparative in vitro activity of ofloxacin. J Antimicrob Chemother. 1988;22 Suppl C:9-19.
19. Cooper MA, Andrews JM, Wise R. In vitro activity of PD 131628, a new quinolone antimicrobial agent. J Antimicrob Chemother. 1992;29:519-27.
20. Bauernfeind A. Comparative in vitro activities of the new quinolone Bay y 3118 and ciprofloxacin, sparfloxacin, tosufloxacin, Cl 960 and Cl 990. J Antimicrob Chemother. 1993;31:505-22.
21. Borobio MV, Conejo MdC, Ramirez E, Suarez AI, Perea EJ. Comparative activities of eight quinolones against members of the Bacteroides fragilis group. Antimicrob Agents Chemother. 1994;38:1442-5.
22. Wise R, Andrews JM, Brenwald N. The in vitro activity of OPC-17116 a new 5-methyl-substituted quinolone. J Antimicrob Chemother. 1993;31:497-504.
23. King A, Boothman C, Phillips I. The in vitro activity of PD 127,391, a new quinolone. J Antimicrob Chemother 1988; 22:135-41.
24. Holt HA, Bowker KE, Reeves DS, MacGowan AP. In vitro studies with clinafloxacin and nine other antimicrobials against over 400 anaerobe strains isolated in the United Kingdom. In: Proceedings and abstracts of The 35th Interscience Conference of Antimicrobial Agents and Chemotherapy. Washington (DC): American Society for Microbiology, 1995:F179.